204 related articles for article (PubMed ID: 18277895)
1. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis.
Tanaka N; Sano K; Horiuchi A; Tanaka E; Kiyosawa K; Aoyama T
J Clin Gastroenterol; 2008 Apr; 42(4):413-8. PubMed ID: 18277895
[TBL] [Abstract][Full Text] [Related]
2. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
Sanyal AJ; Abdelmalek MF; Suzuki A; Cummings OW; Chojkier M;
Gastroenterology; 2014 Aug; 147(2):377-84.e1. PubMed ID: 24818764
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
[TBL] [Abstract][Full Text] [Related]
4. Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats.
Kajikawa S; Harada T; Kawashima A; Imada K; Mizuguchi K
Dig Dis Sci; 2010 Mar; 55(3):631-41. PubMed ID: 19856102
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
Ratziu V; Giral P; Jacqueminet S; Charlotte F; Hartemann-Heurtier A; Serfaty L; Podevin P; Lacorte JM; Bernhardt C; Bruckert E; Grimaldi A; Poynard T;
Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
[TBL] [Abstract][Full Text] [Related]
6. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
[TBL] [Abstract][Full Text] [Related]
8. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Promrat K; Lutchman G; Uwaifo GI; Freedman RJ; Soza A; Heller T; Doo E; Ghany M; Premkumar A; Park Y; Liang TJ; Yanovski JA; Kleiner DE; Hoofnagle JH
Hepatology; 2004 Jan; 39(1):188-96. PubMed ID: 14752837
[TBL] [Abstract][Full Text] [Related]
10. Association between endotoxemia and histological features of nonalcoholic fatty liver disease.
Kitabatake H; Tanaka N; Fujimori N; Komatsu M; Okubo A; Kakegawa K; Kimura T; Sugiura A; Yamazaki T; Shibata S; Ichikawa Y; Joshita S; Umemura T; Matsumoto A; Koinuma M; Sano K; Aoyama T; Tanaka E
World J Gastroenterol; 2017 Jan; 23(4):712-722. PubMed ID: 28216979
[TBL] [Abstract][Full Text] [Related]
11. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis.
Charatcharoenwitthaya P; Levy C; Angulo P; Keach J; Jorgensen R; Lindor KD
Liver Int; 2007 Mar; 27(2):220-6. PubMed ID: 17311617
[TBL] [Abstract][Full Text] [Related]
12. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
Huang MA; Greenson JK; Chao C; Anderson L; Peterman D; Jacobson J; Emick D; Lok AS; Conjeevaram HS
Am J Gastroenterol; 2005 May; 100(5):1072-81. PubMed ID: 15842581
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis.
Li YH; Yang LH; Sha KH; Liu TG; Zhang LG; Liu XX
World J Gastroenterol; 2015 Jun; 21(22):7008-13. PubMed ID: 26078579
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats.
Zhao JS; Zhu FS; Liu S; Yang CQ; Chen XM
Chin Med J (Engl); 2012 Jul; 125(13):2316-21. PubMed ID: 22882855
[TBL] [Abstract][Full Text] [Related]
15. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
Nelson A; Torres DM; Morgan AE; Fincke C; Harrison SA
J Clin Gastroenterol; 2009; 43(10):990-4. PubMed ID: 19448566
[TBL] [Abstract][Full Text] [Related]
16. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.
Capanni M; Calella F; Biagini MR; Genise S; Raimondi L; Bedogni G; Svegliati-Baroni G; Sofi F; Milani S; Abbate R; Surrenti C; Casini A
Aliment Pharmacol Ther; 2006 Apr; 23(8):1143-51. PubMed ID: 16611275
[TBL] [Abstract][Full Text] [Related]
17. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
Ito S; Yukawa T; Uetake S; Yamauchi M
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
[TBL] [Abstract][Full Text] [Related]
18. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin.
Gonciarz M; Gonciarz Z; Bielanski W; Mularczyk A; Konturek PC; Brzozowski T; Konturek SJ
J Physiol Pharmacol; 2010 Dec; 61(6):705-10. PubMed ID: 21224501
[TBL] [Abstract][Full Text] [Related]
19. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.
Dasarathy S; Dasarathy J; Khiyami A; Yerian L; Hawkins C; Sargent R; McCullough AJ
J Clin Gastroenterol; 2015 Feb; 49(2):137-44. PubMed ID: 24583757
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
